No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Source: 
Endpoints
snippet: 

Ahead of the keenly anticipated independent panel set to discuss Aimmune’s peanut allergy immunotherapy on Friday, FDA staff issued a predictable review on Wednesday, highlighting the potential safety and tolerability issues associated with the product, while backing its efficacy.